2seventy bio

The cell and gene therapy sectors are rapidly advancing, with updates on PepGen's PGN-EDO51 IND hold, innovative payment models for high-cost treatments, Janssen and Legend Biotech's Carvykti showing higher MRD negativity rates, Bristol Myers Squibb and 2seventy bio's Abecma responses in CNS-affected MM patients, Editas Medicine discontinuing EDIT-301 development, and SpliceBio's SB-007 receiving IND clearance for Stargardt disease treatment.

Real-world analysis of ide-cel in r/r MM with CNS involvement showed 70% had no CNS relapse post-treatment, with median PFS of 10.5 months and OS of 12.9 months. CAR T-cell therapy demonstrated efficacy and feasibility in this rare form of MM.

The article discusses the implementation of Server-Side Rendering (SSR) through a JavaScript service entry, enhancing performance and user experience.

DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Sanofi, and recent FDA approvals for Roctavian and ALTUVIIIO. The report assesses the therapeutic landscape, including product types, stages, routes of administration, and molecule types.

DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Novo Nordisk, and recent FDA approvals for Roctavian and ALTUVIIIO.

Despite numerous challenges, 2seventy bio, formerly part of bluebird bio, remains focused on achieving profitability with its CAR T therapy Abecma. The company has undergone layoffs, pipeline reorganizations, and faced competition and FDA safety warnings. CEO Chip Baird predicts profitability next year, with potential growth strategies including acquisitions or licensing deals. The company's culture and resilience among its employees have been key to its survival.

Bristol Myers Squibb and 2seventy bio halted the KarMMa-9 trial due to enrollment challenges, despite efforts to facilitate recruitment. Advances in induction therapies have reduced the eligible patient population for the trial. However, ide-cel (Abecma) received FDA approval for expanded use in relapsed/refractory multiple myeloma after two prior lines of therapy, based on positive results from the KarMMa-3 trial.

Bristol Myers Squibb and 2seventy bio halt KarMMa-9 trial enrollment due to fewer eligible patients, attributed to advances in induction therapies leading to higher complete response rates in newly diagnosed multiple myeloma patients post-transplant.

BMS and 2seventy bio halt Phase III KarMMa-9 trial for Abecma in NDMM due to reduced eligible patient population as induction therapies improve, affecting trial viability.

2Seventy bio halts enrollment in a key multiple myeloma study for its therapy Abecma to save $80 million, aiming for financial break-even next year. Despite this, Abecma shows growth, with U.S. revenue expected to rise 30% in Q3. The decision reflects an improved treatment landscape for newly diagnosed patients, reducing eligible participants.